Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

100
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
100
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

137
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
137
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

129
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
129
Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

2.0K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
2.0K
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

112
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
112
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

86
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
86

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The effect of Womersley number and particle radius on the accumulation of lipoproteins in the human aorta.

Computer methods in biomechanics and biomedical engineering·2020
Same author

A Case of a Derivative Chromosome: der(Y)t(Y;18)Pat with Congenital Abnormalities.

Fetal and pediatric pathology·2019
Same author

Clinical application of chromosomal microarray analysis for the diagnosis of Williams-Beuren syndrome in Chinese Han patients.

Molecular genetics & genomic medicine·2018
Same author

Clinical application of chromosomal microarray analysis for the prenatal diagnosis of chromosomal abnormalities and copy number variations in fetuses with congenital heart disease.

Prenatal diagnosis·2018
Same author

[Integrated regional network construction for ST-segment elevation myocardial infarction care].

Zhonghua xin xue guan bing za zhi·2014
Same author

Expression and function of Toll-like receptors in peripheral blood mononuclear cells from patients with ovarian cancer.

Cancer immunology, immunotherapy : CII·2014

Related Experiment Video

Updated: Oct 25, 2025

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.9K

Multi-factor regulatory network and different clusters in hypertrophic obstructive cardiomyopathy.

Xianyu Qin1,2, Lei Huang3, Sicheng Chen3,4

  • 1Department of Thoracic Surgery, Thoracic Cancer Center, The Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

BMC Medical Genomics
|August 7, 2021
PubMed
Summary

This study identifies key genes and regulatory networks in hypertrophic obstructive cardiomyopathy (HOCM). These findings offer potential new avenues for understanding and treating HOCM mechanisms.

Keywords:
Different clustersHypertrophic obstructive cardiomyopathyMulti-factor regulatory networkWeighted gene co-expression network analysis

More Related Videos

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.3K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.8K

Related Experiment Videos

Last Updated: Oct 25, 2025

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level
06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

5.9K
Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

10.3K
Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model
03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

3.8K

Area of Science:

  • Genomics
  • Biomedical Research
  • Cardiovascular Disease

Background:

  • Hypertrophic obstructive cardiomyopathy (HOCM) lacks practical biosignatures and a complete understanding of its regulatory processes.
  • Current knowledge gaps hinder effective diagnosis and treatment strategies for HOCM.

Purpose of the Study:

  • To identify crucial genes and regulatory networks involved in hypertrophic obstructive cardiomyopathy (HOCM).
  • To establish a foundation for potential mechanistic and therapeutic advancements in HOCM.

Main Methods:

  • Integrated public gene expression datasets (GEO, Gene, OMIM) to form a candidate HOCM gene set.
  • Applied Weighted Gene Co-expression Network Analysis (WGCNA) to identify key co-expressed genes.
  • Constructed a multi-factor regulatory network (lncRNAs, mRNAs, miRNAs, TFs) and performed unsupervised clustering to identify hub genes.

Main Results:

  • Identified 32 crucial co-expressed genes within two significant HOCM modules via WGCNA.
  • Disclosed seven primary regulatory agents, including lncRNAs (XIST, MALAT1, H19), TFs (SPI1, SP1), and miRNAs (hsa-miR-29b-39, has-miR-29a-3p).
  • Discovered four HOCM clusters and four hub genes (COMP, FMOD, AEBP1, SULF1) with significant expression differences, validated by ROC curve analysis.

Conclusions:

  • The identified genes and regulatory networks provide a valuable resource for HOCM research.
  • These findings may facilitate future mechanistic and therapeutic explorations in hypertrophic obstructive cardiomyopathy.